definiens: ( ( defined as the initiation of II . given Phase I Clinieal1'rial, complction of . given Phase U Clinical Trial, $ ubmissioD of a given BLA or IIPProval of II . BLA, to the elltent triggering II milestone payment above ) shall result in an obligation to make the corresponding payment obligation evcty time such Milestone Event occurs unless the subsequent occunence of the Milestone Event involves both ! he same Product and ! he ume Indication l1li II . previous Milestone Eveot for which " milestones were already paid . For th'l ~ subtClquent oe<:urrences of I MliCMOne Event involving, for eumple, lhc : Ame Product Ind ovenlJ indicatIOn as the previous Milelcone Event but . diffCRnl lubpopulalion ( W lUbtypc willlin luch indication than the subpopulation or subtype ( if any ) explicitly tarptai in AlCh previOlUl Milestone Event, llhall triiF ' new milestone payment obliptiont hcreundet- ( in m : ognition of the riel that such subpopulation or ad : Mype required . new PhMe I and/or Phae II Clinical Trial aodIor BLA .. lhe cue rnay be ) . Furthermo re, il i. underalOOd and agreed that 00 more than one milC$lone payment ( in the applicable amount specified above, and DOl mUltiplet theroof ) shall be made with rcspocl \0 a given Milestone Event, without limiting lII1y milestones due for a subsequent oteurrence of the IIIIJI1C Milestone Evenl for I different Indication or Product . Thus, for example completion of a given Phase II Clinical Trial for a given Product within the applicable Field will ! rigger only onc payment of 5500,000, regardless of whether the ProdLict in such Lrial was a combination product containing two biological compounds from two different Cell Lines and regardless of whether the Indication targeted in such trial could potentially cover different patient populations or be subdivided into subtypes or subgroups